HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Elmar A. Joura, Susanne K. Kjaer, Cosette M. Wheeler, Kristján Sigurdsson, Ole Erik Iversen, Mauricio Hernandez-Avila, Gonzalo Perez, Darron Brown, Laura A. Koutsky, Eng Hseon Tay, Patricia García, Kevin A. Ault, Suzanne M. Garland, Sepp Leodolter, Sven Eric Olsson, Grace W K Tang, Daron G. Ferris, Jorma Paavonen, Matti Lehtinen, Marc StebenXavier Bosch, Joakim Dillner, Robert J. Kurman, Slawomir Majewski, Nubia Muñoz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Lisa C. Lupinacci, Katherine E D Giacoletti, Shuang Lu, Scott Vuocolo, Teresa M. Hesley, Richard M. Haupt, Eliav Barr

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

Original languageEnglish
Pages (from-to)6844-6851
Number of pages8
JournalVaccine
Volume26
Issue number52
DOIs
StatePublished - Dec 9 2008

Fingerprint

Papillomavirus Vaccines
Human papillomavirus 18
Papillomaviridae
vaccines
antibodies
Antibodies
Vaccines
Humoral Immunity
Placebos
humoral immunity
genitalia
placebos
Serum
testing

Keywords

  • Human Papillomavirus
  • Humoral immunity
  • Immune memory

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Joura, E. A., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., ... Barr, E. (2008). HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine, 26(52), 6844-6851. https://doi.org/10.1016/j.vaccine.2008.09.073

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. / Joura, Elmar A.; Kjaer, Susanne K.; Wheeler, Cosette M.; Sigurdsson, Kristján; Iversen, Ole Erik; Hernandez-Avila, Mauricio; Perez, Gonzalo; Brown, Darron; Koutsky, Laura A.; Tay, Eng Hseon; García, Patricia; Ault, Kevin A.; Garland, Suzanne M.; Leodolter, Sepp; Olsson, Sven Eric; Tang, Grace W K; Ferris, Daron G.; Paavonen, Jorma; Lehtinen, Matti; Steben, Marc; Bosch, Xavier; Dillner, Joakim; Kurman, Robert J.; Majewski, Slawomir; Muñoz, Nubia; Myers, Evan R.; Villa, Luisa L.; Taddeo, Frank J.; Roberts, Christine; Tadesse, Amha; Bryan, Janine; Lupinacci, Lisa C.; Giacoletti, Katherine E D; Lu, Shuang; Vuocolo, Scott; Hesley, Teresa M.; Haupt, Richard M.; Barr, Eliav.

In: Vaccine, Vol. 26, No. 52, 09.12.2008, p. 6844-6851.

Research output: Contribution to journalArticle

Joura, EA, Kjaer, SK, Wheeler, CM, Sigurdsson, K, Iversen, OE, Hernandez-Avila, M, Perez, G, Brown, D, Koutsky, LA, Tay, EH, García, P, Ault, KA, Garland, SM, Leodolter, S, Olsson, SE, Tang, GWK, Ferris, DG, Paavonen, J, Lehtinen, M, Steben, M, Bosch, X, Dillner, J, Kurman, RJ, Majewski, S, Muñoz, N, Myers, ER, Villa, LL, Taddeo, FJ, Roberts, C, Tadesse, A, Bryan, J, Lupinacci, LC, Giacoletti, KED, Lu, S, Vuocolo, S, Hesley, TM, Haupt, RM & Barr, E 2008, 'HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine', Vaccine, vol. 26, no. 52, pp. 6844-6851. https://doi.org/10.1016/j.vaccine.2008.09.073
Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008 Dec 9;26(52):6844-6851. https://doi.org/10.1016/j.vaccine.2008.09.073
Joura, Elmar A. ; Kjaer, Susanne K. ; Wheeler, Cosette M. ; Sigurdsson, Kristján ; Iversen, Ole Erik ; Hernandez-Avila, Mauricio ; Perez, Gonzalo ; Brown, Darron ; Koutsky, Laura A. ; Tay, Eng Hseon ; García, Patricia ; Ault, Kevin A. ; Garland, Suzanne M. ; Leodolter, Sepp ; Olsson, Sven Eric ; Tang, Grace W K ; Ferris, Daron G. ; Paavonen, Jorma ; Lehtinen, Matti ; Steben, Marc ; Bosch, Xavier ; Dillner, Joakim ; Kurman, Robert J. ; Majewski, Slawomir ; Muñoz, Nubia ; Myers, Evan R. ; Villa, Luisa L. ; Taddeo, Frank J. ; Roberts, Christine ; Tadesse, Amha ; Bryan, Janine ; Lupinacci, Lisa C. ; Giacoletti, Katherine E D ; Lu, Shuang ; Vuocolo, Scott ; Hesley, Teresa M. ; Haupt, Richard M. ; Barr, Eliav. / HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. In: Vaccine. 2008 ; Vol. 26, No. 52. pp. 6844-6851.
@article{91f7fe93a1c8405084831fbe80043927,
title = "HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine",
abstract = "The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40{\%} of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4{\%}; 95{\%} CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.",
keywords = "Human Papillomavirus, Humoral immunity, Immune memory",
author = "Joura, {Elmar A.} and Kjaer, {Susanne K.} and Wheeler, {Cosette M.} and Kristj{\'a}n Sigurdsson and Iversen, {Ole Erik} and Mauricio Hernandez-Avila and Gonzalo Perez and Darron Brown and Koutsky, {Laura A.} and Tay, {Eng Hseon} and Patricia Garc{\'i}a and Ault, {Kevin A.} and Garland, {Suzanne M.} and Sepp Leodolter and Olsson, {Sven Eric} and Tang, {Grace W K} and Ferris, {Daron G.} and Jorma Paavonen and Matti Lehtinen and Marc Steben and Xavier Bosch and Joakim Dillner and Kurman, {Robert J.} and Slawomir Majewski and Nubia Mu{\~n}oz and Myers, {Evan R.} and Villa, {Luisa L.} and Taddeo, {Frank J.} and Christine Roberts and Amha Tadesse and Janine Bryan and Lupinacci, {Lisa C.} and Giacoletti, {Katherine E D} and Shuang Lu and Scott Vuocolo and Hesley, {Teresa M.} and Haupt, {Richard M.} and Eliav Barr",
year = "2008",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2008.09.073",
language = "English",
volume = "26",
pages = "6844--6851",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

AU - Joura, Elmar A.

AU - Kjaer, Susanne K.

AU - Wheeler, Cosette M.

AU - Sigurdsson, Kristján

AU - Iversen, Ole Erik

AU - Hernandez-Avila, Mauricio

AU - Perez, Gonzalo

AU - Brown, Darron

AU - Koutsky, Laura A.

AU - Tay, Eng Hseon

AU - García, Patricia

AU - Ault, Kevin A.

AU - Garland, Suzanne M.

AU - Leodolter, Sepp

AU - Olsson, Sven Eric

AU - Tang, Grace W K

AU - Ferris, Daron G.

AU - Paavonen, Jorma

AU - Lehtinen, Matti

AU - Steben, Marc

AU - Bosch, Xavier

AU - Dillner, Joakim

AU - Kurman, Robert J.

AU - Majewski, Slawomir

AU - Muñoz, Nubia

AU - Myers, Evan R.

AU - Villa, Luisa L.

AU - Taddeo, Frank J.

AU - Roberts, Christine

AU - Tadesse, Amha

AU - Bryan, Janine

AU - Lupinacci, Lisa C.

AU - Giacoletti, Katherine E D

AU - Lu, Shuang

AU - Vuocolo, Scott

AU - Hesley, Teresa M.

AU - Haupt, Richard M.

AU - Barr, Eliav

PY - 2008/12/9

Y1 - 2008/12/9

N2 - The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

AB - The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

KW - Human Papillomavirus

KW - Humoral immunity

KW - Immune memory

UR - http://www.scopus.com/inward/record.url?scp=56949087305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949087305&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.09.073

DO - 10.1016/j.vaccine.2008.09.073

M3 - Article

C2 - 18930097

AN - SCOPUS:56949087305

VL - 26

SP - 6844

EP - 6851

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -